Research has shown that the expressions of NOD1, NOD2, NLRP3, caspase-1, and the release of IL-1β, IL-18, and TNF-α were upregulated in NAFLD intestine and reduced after treatment of BBR. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.